In another randomized clinical trial with dapagliflozin in T2DM patients with NAFLD, reduced GGT and ALT levels in the serum of the dapagliflozin-treated group were reported [53]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.